Stockscreener 앱 받기
15.46
1.72%
-0.27
시간 외 거래:
15.00
-0.46
-2.98%
전일 마감가:
$15.73
열려 있는:
$15.66
하루 거래량:
646.79K
Relative Volume:
0.52
시가총액:
$2.64B
수익:
-
순이익/손실:
$-382.71M
주가수익비율:
-5.9008
EPS:
-2.62
순현금흐름:
$-325.64M
1주 성능:
-1.59%
1개월 성능:
-8.47%
6개월 성능:
-24.25%
1년 성능:
-45.02%
1일 변동 폭
$15.16
$16.09
1주일 범위
$15.16
$16.55
52주 변동 폭
$12.72
$34.47
Immunovant Inc Stock (IMVT) Company Profile
명칭
Immunovant Inc
전화
917-580-3099
주소
320 WEST 37TH STREET, NEW YORK, NY
IMVT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
15.46 | 2.73B | 0 | -382.71M | -325.64M | -2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-03-03 | 개시 | Jefferies | Hold |
| 2025-01-03 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-10-09 | 재확인 | Oppenheimer | Outperform |
| 2024-03-28 | 개시 | Oppenheimer | Outperform |
| 2024-03-13 | 개시 | Goldman | Buy |
| 2024-02-20 | 개시 | JP Morgan | Overweight |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-13 | 업그레이드 | UBS | Neutral → Buy |
| 2023-09-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | 개시 | BofA Securities | Buy |
| 2023-04-25 | 개시 | Citigroup | Buy |
| 2023-03-31 | 개시 | Piper Sandler | Overweight |
| 2023-03-30 | 개시 | Stifel | Buy |
| 2023-02-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-01-03 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2021-08-03 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-06-01 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-10-12 | 개시 | Guggenheim | Buy |
| 2020-10-08 | 개시 | Stifel | Buy |
| 2020-10-02 | 개시 | Credit Suisse | Outperform |
| 2020-08-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-07-29 | 개시 | H.C. Wainwright | Buy |
| 2020-02-24 | 개시 | SVB Leerink | Outperform |
모두보기
Immunovant Inc 주식(IMVT)의 최신 뉴스
Candlestick Reversal Detected on Immunovant Inc.’s ChartReal Time Alerts Based on AI Prediction Triggered - metal.it
Is Immunovant Inc. a growth stock or a value stockStrong return on investment - Jammu Links News
How does Immunovant Inc. compare to its industry peersAchieve rapid portfolio appreciation today - Jammu Links News
What are the technical indicators suggesting about Immunovant Inc.Massive wealth growth - Jammu Links News
Is Immunovant Inc. a good long term investmentFastest-growing stock picks - Jammu Links News
Should I hold or sell Immunovant Inc. stock in 2025Sky-high return potential - Jammu Links News
When is Immunovant Inc. stock expected to show significant growthTriple-digit growth rates - Jammu Links News
How volatile is Immunovant Inc. stock compared to the marketUnmatched market gains - Jammu Links News
What drives Immunovant Inc. stock priceCapitalize on market opportunities with confidence - Jammu Links News
What institutional investors are buying Immunovant Inc. stockOutperformance with explosive growth - Jammu Links News
Is it the right time to buy Immunovant Inc. stockFree Stock Movement Tracking - Jammu Links News
What catalysts could drive Immunovant Inc. stock higher in 2025Breakthrough wealth creation - Jammu Links News
Is Immunovant Inc. stock overvalued or undervaluedBuild a portfolio that outperforms the market - Jammu Links News
What are analysts’ price targets for Immunovant Inc. in the next 12 monthsOutstanding growth strategies - Jammu Links News
How does Immunovant Inc. generate profit in a changing economyFree Capital Growth Strategies - Jammu Links News
What analysts say about Immunovant Inc. stockCapitalize on market momentum for big wins - Jammu Links News
How many analysts rate Immunovant Inc. as a “Buy”Get daily updates on top-performing stocks - Jammu Links News
Why is Immunovant Inc. stock attracting strong analyst attentionMaximize gains with expert trading strategies - Jammu Links News
LifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PT - MSN
What makes Immunovant Inc. stock price move sharplyBest Dividend Outlook For Consistent Profits - Jammu Links News
Immunovant appoints Eric Venker as CEO with new compensation agreement By Investing.com - Investing.com Canada
Immunovant Appoints Eric Venker as New CEO - TipRanks
Momentum Screeners Rank Immunovant Inc. in Top 5 TodayReversal Alert Based on RSI Indicator Confirmed - metal.it
Immunovant Inc. Hits Oversold Level on RSI IndicatorProfit Focused Stock Screener Results Released - metal.it
Immunovant Inc. stock volume spike explainedFree Fast Return Equity Trade Forecast - Newser
Immunovant Inc. stock daily chart insightsFree Risk Controlled Short Term Trade Plans - Newser
Can momentum traders help lift Immunovant Inc.Chart Driven Entry Timing for Swing Trades - Newser
Immunovant Inc. Company Revenue and Profit Trends: A Deep DiveFree Real-Time Stock Data - metal.it
What is the dividend policy of Immunovant Inc. stockInvest smarter with real-time trading signals - jammulinksnews.com
Immunovant (IMVT) Gets a Buy from Cantor Fitzgerald - The Globe and Mail
Bank of New York Mellon Corp Reduces Holdings in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Cantor Fitzgerald's Schmidt FCA Reiterates Buy Rating on Immunovant with a $37.22 Average Price Target. - AInvest
Immunovant Executives Sell Shares to Cover Tax Obligations - TradingView
Can Immunovant Inc. stock recover from recent declineHigh-profit stock alerts - jammulinksnews.com
Immunovant Plunges 7.64%, Is This a Buying Opportunity or a Warning Sign? - AInvest
Immunovant CMO and CTO sell shares at $18.15 on July 23, 2025. - AInvest
Immunovant Inc (IMVT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):